Efficacy & Safety Drug Study for Patients with Primary Immune Thrombocytopenia (ITP)
Phase 3, multicenter, randomized, double-blinded, placebo-controlled, parallel-group, up to 31-week trial to evaluate the efficacy, safety, and impact on QoL of efgartigimod 10 mg/kg IV treatment in adult patients with primary ITP.
HEALTHY PARTICIPANTS: No
University Hospitals Cleveland Medical Center is offering a research study to investigate the effect (efficacy) and the safety of a drug called “efgartigimod (ARGX-113)” in people with primary immune thrombocytopenia (ITP). The study will collect information on how well efgartigimod works, how your body processes efgartigimod, what efgartigimod does to your body, and how your immune system reacts to efgartigimod.
Who Can Participate
Patients who are 18 years and older and diagnosed with ITP for at least 3 months prior to randomization and have a platelet counts of <30 x 10^9/L may be eligible for the study.
Learn More About This Research Study
For more information, please call study coordinator, Katie Northcutt at 216-286-0220 or contact us online using the form below.